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ABSTRACT 
 
PURPOSE: To develop, assess the feasibility of, and determine the clinical validity of an 
event-based analysis method using wearable monitors to quantify walking pain 
manifestations (WPMs) and stops induced by walking pain (SIWPs) during daily life walking 
in people with peripheral artery disease (PAD). 
METHODS: The following two walking conditions were studied: a standardized outdoor 
walking session (OWS) and a 7-day free-living measurement (FLM) period. The PAD 
participants (n=23) wore an accelerometer and a watch. They were asked to press the event 
marker button on the watch to indicate events related to WPMs and SIWPs. To assess the 
clinical validity of the method, the computed pain-free walking time (PFWT) and maximal 
walking time (MWT) were compared to the PFWT and MWT assessed using standard 
treadmill walking protocols, respectively. 
RESULTS: Following OWSs, the PFWT
[OWS]
 and MWT
[OWS]
 were significantly correlated
with the PFWT
[Strandness]
 (r=0.955, P<0.001) and MWT
[Strandness]
 (r=0.821, P<0.001),
respectively. During the FLM, PAD participants experienced only 2 WPMs/day and 1 
SIWP/day, although severely limited on the treadmill and during the OWS. The average 
WPMs/day were moderately correlated with the PFWT
[Strandness] 
(r=-0.54, P=0.016). The
PFWT
[FLM]
 was on average 12 times longer than the PFWT
[Strandness]
. Interestingly, the
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intensity of the walking bouts as assessed by the accelerometer counts during the FLM was 
significantly lower than that during the OWS (45±15 vs. 66±21 counts/s, P<0.001). 
CONCLUSION: This new method provides perspectives for studies investigating the 
experience of living with PAD and the assessment of daily life walking capacity for both 
diagnostic and therapeutic purposes. 
 
KEY WORDS: physical activity; walking; intermittent claudication; accelerometry; event 
history analysis 
 
Clinical Trail Registration: https://clinicaltrials.gov/ct2/show/NCT02041169 
 
INTRODUCTION 
Lower extremity peripheral artery disease (PAD) is a chronic atherosclerotic occlusive 
disease that causes insufficient blood flow to the lower extremities, which can manifest as 
ischemic walking pain in the lower limbs and impair walking in people with PAD
1
. For both
diagnostic and therapeutic purposes, assessing lower limb pain manifestation and the 
associated walking impairment is an important aspect of PAD management
2
. The “gold
standard” method for such an assessment is the measurement of the pain-free walking time 
(PFWT) or distance and the maximal walking time (MWT) or distance during a treadmill 
walking test
2
. The MWT has been reported to be more reliably estimated than the PFWT
3
.
However, the joint estimation of PFWT and MWT during walking crucial for fully assessing 
the pain experienced by people with PAD particularly because different treatment options can 
differentially impact the pain trajectory during walking 
4
, leading to independent changes in
the PFWT and MWT
5
.
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Although the treadmill assessment of the PFWT and MWT is well standardized and has been 
extensively studied
3
, it remains protocol dependent, technically demanding, time-consuming,
and limited to vascular laboratories. Furthermore, the maximal treadmill walking distance can 
exhibit substantial variation relative to the “true” outdoor walking capacity while walking at a 
usual pace on a flat surface
6-8
 and does not reflect the patient’s perceived disability3,9,10. This
issue is a serious concern for clinical decision-making and research purposes because the 
consensus opinion supports that the optimal functional test should be correlated with patient-
reported ambulatory function in daily life
11-14
.
An accurate ambulatory measurement of the outdoor walking capacity has been proposed 
using Global Positioning System (GPS) receivers
6,7,15,16
. However, as currently used, the
onset of walking pain cannot be retrieved from an analysis of a GPS speed signal, which 
precludes the estimation of the PFWT and a full assessment of the pain experienced during 
“natural” outdoor walking. Furthermore, the GPS assessment of the daily walking capacity is 
limited in time (a 45- to 60-minute outdoor walking session (OWS)), space (outdoors), 
feasibility (may depend on the weather conditions), and clinical interpretation (stops having 
to be induced by lower limb pain only), which may preclude an extended analysis of the 
walking capacity under complete free-living conditions
7
. Therefore, using seven-day
continuous ambulatory monitoring with an activPAL™ monitor, Clarke et al. developed a 
method for performing an event-based analysis to quantify the fragmented nature of walking 
bouts in people with PAD with intermittent claudication
17
. However, this method did not
enable clinicians to determine whether the stops between bouts of walking were due to 
exertional pain induced by ischemia. Thus, a method for assessing walking pain 
manifestations (WPMs) is required to fully assess and understand the pattern of lower limb 
pain manifestation and the related functional impairment during daily life walking
18
.
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The aims of this study were as follows: (i) the assessment of the feasibility of tracking and 
quantifying WPMs and stop(s) induced by walking pain (SIWPs) using wearable monitors 
during an OWS in PAD participants; (ii) development of an event-based analysis method 
using wearable monitors to quantify WPMs and SIWPs during daily life in PAD participants; 
and (iii) determination of the clinical validity of the computed PFWT and MWT derived from 
the recording of WPMs and SIWPs, respectively. 
 
MATERIALS AND METHODS 
 
Study overview 
This cross-sectional study was a part of the “CLASH” project (NCT02041169), which was 
approved by the local institutional ethics committee of Rennes (CPP OUEST V, Rennes, 
France). People with PAD were recruited from our Vascular Medicine Unit (University 
Hospital, Rennes, France) during their medical appointment, which included a treadmill test 
(eligibility visit). The subjects who met the inclusion criteria (Table 1) were invited to 
participate. Then, within a 1-month period, the included PAD participants underwent the 
following: a laboratory assessment of their walking capacity, a 45-60 min OWS, and a 7-day 
free-living measurement (FLM). 
 
The aim of the OWS was first to determine the ability of the PAD participants to record 
events related to ischemic pain while walking (i.e., WPM and SIWP) using a Micro 
Motionlogger® Watch worn at the wrist level. Second, we aimed to determine the PFWT and 
the MWT based on the WPM and SIWP events, respectively, to analyze their associations 
with the treadmill measures and assess the clinical validity of these assessments. 
The aim of the 7-day FLM was to implement an event-based analysis by combining the data 
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from the watch and accelerometer to determine the free-living walking limitations (PFWT 
and MWT) and their association with the treadmill measures. 
 
Experimental procedure 
Laboratory assessment of the walking capacity. During the first visit (inclusion visit), the 
participants’ sex, weight, height, cardiovascular risk factors, comorbid conditions, 
claudication history and list of current medications were obtained through the medical 
histories and medical reports. Self-reported ambulatory walking impairment was assessed 
using the WIQ, and the quality of life was evaluated using the SF-36 questionnaire. The 
lower limb symptoms experienced by the PAD participants were assessed and classified 
using the San Diego claudication questionnaire
19
 and the categories of leg symptoms
modified by McDermott et al.
20
 The resting ankle-brachial index was measured using a
handheld Doppler probe according to the recommendations of the American Heart 
Association
21
. Then, the PAD participants performed a Gardner-Skinner treadmill protocol
(3.2 km/h, 0% grade with 2% increase every 2 minutes) until reaching maximal claudication 
pain. On another day, the PAD participants also performed a Strandness treadmill protocol 
(3.2 km/h, 10% grade) until reaching maximal claudication pain. During both treadmill tests, 
the PFWT and the MWT were recorded. 
 
Outdoor walking session. The PAD participants performed an OWS on a dedicated day that 
consisted of walking at their usual walking speed for 45 to 60 min, including eventual bouts 
of stopping (recovery) due to lower-limb pain. The participants were asked to stop walking 
only due to lower-limb pain and were given no recommendations regarding the minimal or 
maximal duration of the stops. The OWSs occurred on a designated athletic track (0% grade) 
that was free of buildings and compact trees. Rainy days were avoided. 
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The PAD participants were equipped with (i) a Micro Motionlogger® Watch (Ambulatory 
Monitoring, Inc., Ardsley, NY; firmware Action-W version 2); (ii) a DG100 GPS receiver 
(GlobalSat, Taipei, Taiwan); and (iii) a wGT3X+ accelerometer (ActiGraph
TM
, LLC,
Pensacola, FL; firmware version: 2.2.1 to 2.4.0). The watch was used to record the WPMs 
and SIWPs. This device is a small (3.63.61.2 cm) and light (30 g) digital wrist watch-sized 
microprocessor that senses motion and enables the user to generate an event marker in the 
recording data file. The device was initialized at a 5-s recording epoch. The DG100 GPS 
receiver (dimensions 80×55×18 mm, weight ~200 g) was used to assess the walking capacity 
of the PAD participants during the OWS as previously described
15
. The DG100 includes the
European Geostationary Navigation Overlay Service function, which was activated during 
the measurements. The DG100 was set at a 1-Hz recording rate using a personal computer 
and the manufacturer’s software (Data Logger Utility, version 1.1). Then, the DG100 unit 
was placed into a plastic pocket with an external antenna (AT-65 GPS Active Antenna; 
GlobalSat) fixed to the top of the pocket shoulder strap. The wGT3X+ is a small 
(4.63.31.5 cm) and light (19 g) tri-axial accelerometer that was used to quantify the 
intensity of the walking bouts for the subsequent comparison with the 7-day FLM. This 
device was initialized at a 30-Hz recording rate using Actilife 6 software (ActiGraphTM, 
LLC, Pensacola, FL; version 6.5.3), placed in a nylon pouch with the Velcro closures 
supplied by the manufacturer and placed at the right hip (on the iliac crest). The monitors 
were synchronized using the same computer clock (Universal Time Coordinated). 
During the OWS, the participants were asked to use the watch and push a specific marker 
button to record (i) pain manifestations in the lower limbs while walking (WPMs) and (ii) 
stops due to lower limb pain (SIWPs). To record a WPM, the participants were asked to press 
the marker button of the watch once. To record an SIWP, the participants were asked to 
consecutively press the marker button twice. 
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The walking session was supervised by two investigators who walked approximately 10 
meters behind the participant. During the walking session, using a chronometer, the 
investigators reported the time when the patient pressed the marker button of the watch to 
indicate a WPM or SIWP. 
 
7-day free-living measurement. The participants were asked to wear a wGT3X+ and the 
watch for seven consecutive days. The devices were initialized and worn as described during 
the OWS (see above). Notably, for the watch, the 5-s recording rate was the highest recording 
rate available for recording data for at least seven full days. The monitors were synchronized 
using the same computer clock (Universal Time Coordinated). The participants were 
carefully instructed to wear the wearable monitors throughout the day for seven consecutive 
days and remove the monitors during water-based activities (e.g., showering and swimming) 
and at bedtime (the watch could be worn during the night at the convenience of the patient). 
Throughout the entire recording period, the participants were asked to push the event marker 
button of the watch to indicate a WPM (1 push) and an SIWP (≥2 pushes). The participants 
were asked to perform their activities as usual. At the end of each day, the participants 
reported the main indoor and/or outdoor activities carried out throughout the day in a specific 
notebook with a timestamp. A booklet containing all instructions regarding the use of the 
monitors and completion of the notebook was also delivered to each patient. During the entire 
recording period, the participants received a short message each morning to remind them to 
wear the monitors. At the end of the 7-day monitoring period, a visit was scheduled, and the 
participants returned the monitors. An investigator also asked the participants questions 
regarding any discomfort caused by the monitors and protocol compliance. 
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Data analysis 
Questionnaires. The responses to the WIQ and SF-36 questionnaires were recorded using a 
spreadsheet and scored following the recommended procedures 
22-25
. Each component of the
WIQ was scored to obtain the WIQ
[Distance]
, WIQ
[Speed]
 and WIQ
[Stairs]
 subscale scores. A WIQ
total score (WIQ
[Total]
) was also computed by averaging the three subscale scores. The WIQ
scores ranged between 0 and 100%, with 100% indicating no impairment. Following the 
scoring of the SF-36, 8 scale scores for 8 items were computed; each item reflects different 
domains of the quality of life, and each domain is scored on a scale ranging from 0 to 100, 
with 100 representing the highest possible score (best possible health status). 
Outdoor walking session. For each walking session, the mean values of the weather 
parameters (temperature (C°), relative humidity (RH in %), wind speed (km/h), and 
barometric pressure (hPa)) were recorded using the information provided by French weather 
stations. The event markers recorded by the watch were also downloaded to a computer using 
Ambulatory Monitoring software (Action-W version 2). These markers were available in a 
specific column of the data file and processed using Excel® 2016 (Microsoft, Redmond, 
WA). For each watch data file, we determined whether an event marker was inserted into the 
data file and whether it was consistent with the event observed by the investigators (i.e., a 
WPM or SIWP). We also identified the time stamp corresponding to the WPM or SIWP 
recorded in the data file and the number of times the button was pressed to record the event. 
We also determined the time difference between the watch-recorded and observed WPMs 
and SIWPs. Finally, for each WPM and SIWP identified from the watch, we computed the 
PFWT and the MWT of the OWS (PFWT
[OWS]
 and MWT
[OWS]
, respectively). For each
patient, we computed both the average (from all walking bouts) and the higher (longer 
walking bout) PFWT
[OWS]
 and MWT
[OWS]
.
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The raw acceleration data recorded by the wGT3X+ were downloaded to a computer. Then, 
the raw data were accumulated into 1-s epoch data (i.e., into counts/s) using the Low 
Frequency Extension (LFE) filter available in the Actilife 6 software (version 6.5.3) to 
compute the counts/s on the vector magnitude (VM). Then, for each walking and stopping 
bout identified from the GPS analysis, the mean±standard deviation of the VM was 
calculated. The GPS data were downloaded to a personal computer using the manufacturer’s 
software (DataLogger Utility, version 1.1) and processed according to a previously published 
procedure
7,26
. The GPS parameters recorded for each patient included the total distance
walked, the entire duration of the outdoor session, the number of walking bouts, the mean 
walking speed calculated over each walking bout, the various walking times between two 
SIWPs and over each walking bout, the higher MWT between two SIWPs per patient during 
the entire walking session, and the duration of the stop preceding each walking bout. 
7-day free-living measurement. Both the wGT3X+ and the watch data were downloaded as 
described for the OWS. The data files were exported to spreadsheets for further analysis. 
Identifying valid days. The wGT3X+ and watch data were screened for valid wear days. A 
valid wear day consisted of at least 10 hours of wear time. From the watch recording, the 
wear time periods were identified using the “Life measures signal” function as suggested by 
the manufacturer. These life measurements sense body vibrations from essential tremors and 
the ballistic heart signal. The absence of this signal is an indication that the watch is no 
longer on the body. From the wGT3X+ recordings, the nonwear time periods were identified 
using the method described by Choi et al
27
. Briefly, the nonwear time was defined as 90
consecutive minutes of zero counts (V-axis counts), with an allowance of 2-minute intervals 
of nonzero counts with an up/downstream 30-minute consecutive zero count window. 
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Matching the data. The data from each monitor were processed using a custom MATLAB
®
code to generate a single Excel
®
 spreadsheet per participant that contains the data recorded
by each wearable monitor, and the data were synchronized with each other and a one-second 
time stamp. 
Labeling event markers from the Micro Motionlogger™ watch. We developed an event-based 
analysis method to label each event marker recorded by the watch, i.e., WPMs and SIWPs. 
The labeling methodology was applied to each event marker that appeared during a day 
considered valid for both the watch and wGT3X+ data. The methodology is presented in 
Figure 1. As shown in Figure 1 (left panel), the methodology first relied on discriminating the 
walking bouts from the non-walking bouts using the VM count data recorded by the 
wGT3X+. This approach consisted of using a counts/s threshold as previously proposed to 
identify sedentary behavior in adults in free-living environments
28
. A bout was considered a
walking bout if the count/s values were above the predefined count
 
threshold for at least 15 s. 
In contrast, a bout was considered a stopping bout if the count/s values were below the 
predefined count
 
threshold for at least 15 s. The rationale for using a minimum duration of 15 
s to define the walking and non-walking bouts was that walking-induced ischemia was 
unlikely to appear (during walking) or disappear (during stopping) within such a short 
period
15,16
. Then, each event was assigned to the following three distinct categories: (i)
WPM; (ii) SIWP; (iii) or “inconsistent”. For both WPMs and SIWPs, we removed duplicate 
events related to ischemic events (multiple presses related to the same WPM or SIWP event 
performed by the participants to ensure that the events were recorded). Otherwise, all other 
events were labeled “inconsistent”. Finally, for each WPM and SIWP identified from the 
watch, we computed the PFWT and the MWT of the FLM (PFWT
[FLM]
 and MWT
[FLM]
,
respectively). For each patient, we computed both the average (from all walking bouts) and 
the highest (longer walking bouts) PFWT
[FLM]
 and MWT
[FLM]
.
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Coding diaries. The notebook information was coded using the Compendium of Physical 
Activities
29
. Finally, each event was matched using the encoding notebook and then analyzed.
A typical example of event identification and qualification is illustrated in Figure 1 (right 
panel, A & B). 
Physical activity level. The physical activity level was assessed as the time spent in the 
different physical activity categories and was determined using the V-axis counts recorded by 
the wGT3X+ (sedentary: <100 counts/min; light: between 100 and 759 counts/min; 
moderate: between 760 and 5724 counts/min; and vigorous: >5724 counts/min)
30
. The time
spent in the different physical activity categories was also expressed as a percentage of the 
wear time (%/day). We also calculated the number of bouts ≥10 minutes with a V-axis level 
≥760 counts/minute. Because WPMs are expected to occur during the continuous walking 
period, no drop time was allowed. The metrics were computed with Actilife® software 
(ActiGraphTM, LLC, Pensacola, FL; version 6.5.3). 
 
Statistical analysis 
The normal distribution of the data of each variable of interest was assessed using the 
Shapiro-Wilk test. Accordingly, the data of the continuous variables are reported as the 
mean±standard deviation or medians with the interquartile range (IQR=25th-75th percentiles),
while the data of the categorical variables are expressed as percentages. The pairwise 
correlations between variables of interest were investigated by calculating the Pearson or 
Spearman correlation coefficients according to the distribution of the data. In addition, 
pairwise comparisons were performed using either the paired samples t-test or Wilcoxon 
signed-rank test according to the distribution of the data. Multiple comparisons of the PFWT 
or MWT between each condition (Strandness, Gardner, OWS, and FLM) were performed 
using the Friedman test (non-normal data). For P<0.05, following the Friedman test, a 
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pairwise comparison was performed between each pair of variables using the Wilcoxon 
Signed-Rank test with a Bonferroni correction of the P-values. All statistical analyses were 
performed using SPSS software (version 23.0.0.2). The level of significance was set at 
P<0.05. 
 
RESULTS 
 
Characteristics of the included PAD participants 
In total, 23 participants were included in the present study. The participants’ characteristics 
are presented in Table 2. The mean age of the included PAD participants was 60±10 years, 
and most (87%) participants were male subjects. The median ABI [IQR] was 0.61 
[0.53;0.75], indicating a mild to moderate PAD severity. Two PAD participants had to stop 
their participation before the end of the study, resulting in two missing Strandness walking 
tests. Due to the uncontrolled treatment of hypertension, one of the two participants 
experienced a severe episode of orthostatic hypotension during the recovery from the 
Strandness treadmill walking test. The other patient underwent vascular intervention. 
However, the results of the Gardner walking test, the OWS and the FLM were available for 
these two participants. During the treadmill tests, all PAD participants experienced lower 
limbs pain forcing them to stop walking and that was relieved or lessened within 10 minutes 
of rest. Following the Gardner-Skinner treadmill test, the PFWT and MWT were 131 s 
[89;224] and 289 s [203;420], respectively. Following the Strandness treadmill test, the 
PFWT and MWT were 79 s [56;105] and 178 s [116;213], respectively. 
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Outdoor walking session 
Table 3 presents an overview of the data obtained from the 23 participants during the OWS. 
All PAD participants reported walking pain during the OWS, and the median [IQR] number 
of stops induced by pain was 6 [4-10]. 
Feasibility of event recording using the watch. Observation-based events were not reported 
by the investigators in one subject, and in another subject, the watch was not available on the 
day of the OWS. In three other subjects, in total, five events were not reported by the 
investigators. Overall, the validity of the event recording using the watch could be studied in 
21 subjects and over 170 walking bouts. 
As shown in Table 3, in total, 126 WPMs were observed by the investigators. The number of 
WPMs recorded by the watch was 115 (91%). At the patient level, the missing WPM events 
only involved three participants, and more than 70% of the missing events were related to 
one patient. In total, 170 SIWPs were observed by the investigators. The number of SIWPs 
was higher than the number of WPMs because some PAD participants resumed their walk 
before the pain in their lower limb(s) had fully disappeared (n=7 participants). Over the 170 
SIWPs, 153 (90%) were recorded on the watch. The 10% of SIWPs that were missing on the 
watch were due to either the patient not pressing the watch or the patient pressing the button 
incorrectly when stopping due to ischemic pain. 
Despite the ~10% missing case rate in the recordings of the WPMs or SIWPs using the 
watch, because the PAD participants usually performed multiple walking bouts during their 
OWS, the PFWT could not be computed in only one patient (with no WPM). Comparing the 
times at which the WPMs and SIWPs were recorded on the watch and the time they were 
observed by the investigators, a mean difference of 4±12 s for the WPMs and 1±5 s for the 
SIWPs was found. This finding translated into nearly perfect correlation coefficients between 
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the average PFWT computed from the watch and that computed from the observations 
(r=0.967, n=19, P<0.001) and between the average MWT computed from the watch and that 
computed from the observations (r=0.992, n=21, P<0.001). 
Relationship with treadmill walking tests and questionnaires. Compared to the results of the 
Strandness treadmill test (Table 2), the PFWT
[OWS]
 and the MWT
[OWS]
 (Table 3 and Figure 2)
were significantly higher (P<0.001). The differences were statistically significant compared 
to the PFWT
[GARDNER]
 (P=0.014) but not the MWT
[GARDNER]
 (P=0.297). The PFWT
[OWS]
 and
MWT
[OWS]
 were significantly correlated with the Strandness PFWT (r=0.955, n=17, P<0.001)
and MWT (r=0.821, n=19, P<0.001), respectively (Appendix #1). Significant associations 
were also found between the PFWT
[Gardner]
 and the PFWT
[OWS] 
(r=0.721, n=18, P=0.001) and
between the MWT
[Gardner]
 and the MWT
[OWS] 
(r=0.446, n=21, P=0.043), although the
correlation coefficients were lower (Appendix #1). The PFWT
[OWS]
 and MWT
[OWS]
 were also
significantly correlated with the WIQ subscale and total scores and the physical functioning 
score computed from the SF-36 questionnaire (Appendix #2). In addition, the physical 
component summary score was moderately correlated with the PFWT
[OWS]
 (r=0.467, n=19,
P=0.044). 
As shown in Appendices #1 and #2, one patient had a higher walking capacity than the 
remaining PAD participants. Removing this patient from the correlation analyses only had an 
effect on the correlations with the MWT
[Gardner]
, the WIQ
[Speed]
 subscale scores and the SF36
scores (the correlations were no longer significant). 
 
7-day free-living measurement 
Acceptability and compliance with the use of the wearable monitors. Four and two 
participants reported experiencing discomfort from the watch (wrist skin irritation) and belt 
of the wGT3X+, respectively. Another patient reported that the wearable monitors were 
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perceived as psychologically disturbing (feeling that he/she was being continuously 
monitored). Three participants reported that they did not systematically press the event 
marker button of the watch to indicate WPMs. One patient only wore the wGT3x+ for 2 days 
and the watch for 4 days of the 7 days and was excluded from subsequent analyses. Thus, 
among the expected total of 161 days of recording (7 days23 participants), 150 (93%) days 
were considered valid for the watch and 148 (92%) days were considered valid for the 
wGT3X+; of these days, 146 days were valid for both monitors. All remaining participants 
included in the analysis (n=22) had at least five valid days of data from the two wearable 
monitors, including at least one weekend day, and 73% (16/22) of the participants had seven 
valid days of data from both wearable monitors. 
Lower limb pain manifestations and associated functional limitations during daily life 
walking. 
Among the 146 valid days available for analysis, 107 days were associated with one or more 
event markers, leading to a total of 670 events among the 22 participants. Among the 670 
event markers recorded, 55 (8%) events were labeled “inconsistent”. These “inconsistent” 
events occurred either at random during a resting period far from the stopping point of a 
walking bout (n=51) or, more rarely, at the beginning of a walk (n=4). 
After removing duplicate pushes related to pain or stop events, the final number of WPMs 
and SIWPs collected among the 22 participants was 368, and high heterogeneity was 
observed among the PAD participants (range: 0-49/week, see Figure 3). No WPMs or SIWPs 
were reported in one patient, and only four of the 22 participants experienced WPMs or 
SIWPs on a daily basis. As shown in Table 4, overall, the PAD participants experienced a 
low number of WPM or SIWP events during the seven days of the free-living recording. The 
PAD participants experienced many more WPMs than SIWPs, and only 16% of the WPMs 
led to SIWPs. Considering only the number of valid days at the group level, on average, the 
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PAD participants experienced a WPM only twice per day and an SIWP only once a day 
(Table 4). As shown in Table 4, this group of PAD participants spent 64% [52-72] of their 
daily time engaging in sedentary behavior and 8% [5-15] of their time engaging in moderate 
to vigorous physical activity. Furthermore, the number of bouts ≥10 minutes with a string of 
consecutive counts values ≥760 counts/minute was very low, i.e., 2 [1-8]. Using the 
notebook, the context in which each event related to WPMs or SIWPs occurred could be 
identified for 288 of 368 events (78%) because some participants sometimes did not complete 
the diary properly. Most (72%) WPM or SIWP events occurred while the participants were 
outside their home. 
When calculating the 7-day FLM maximal PFWT from the WPMs and the maximal MWT 
from the SIWPs, we found that PFWT
[FLM]
 and MWT
[FLM]
 were on average 6 times higher
than PFWT
[OWS]
 (P<0.001) and 3 times higher than MWT
[OWS]
 (P=0.009). In addition, the
PFWT
[FLM]
 was on average 12 times longer than the PFWT
[Strandness]
 (Figure 2 and Table 4).
The related intensity of the walking bouts as assessed by the VM mean counts was also 
significantly lower during the FLM than that during the OWS (45±15 vs. 66±21 counts/s, 
P<0.001). Moderate but significant inverse correlations (Appendix #3) were found between 
the mean WPM/day and the MWT
[GARDNER]
 (r=-0.472, n=22, P=0.027), the PFWT
[Strandness]
(r=-0.543, n=19, P=0.016), the MWT
[Strandness]
 (r=-0.527, n=20, P=0.017), the PFWT
[OWS]
 (r=-
0.473, n=19, P=0.041), and the WIQ
[Distance]
 subscale score (r=-0.438, n=22, P=0.041).
However, these correlations should be interpreted with caution considering the low number 
of WPMs/day experienced by the PAD participants. The very low number of SIWPs 
experienced by the participants precluded any robust correlation analysis. 
 
A
cc
ep
te
d 
A
rt
ic
le
. 
DISCUSSION 
To the best of our knowledge, this study is the first to propose an event-based analysis 
method using a combination of wearable monitors to identify and quantify lower limb WPMs 
and associated functional limitations (SIWPs) in PAD participants while walking under free-
living conditions. 
The main results can be summarized as follows: (i) the use of the watch to report WPMs or 
SIWPs during a 45 to 65-minute OWS showed a high feasibility with only a 10% missing 
data rate; (ii) both the PFWT and the MWT computed from the identification of WPMs and 
SIWPs using the watch during the OWS were significantly correlated with the PFWT
[Strandness]
and MWT
[Strandness]
; and (iii) although severely limited with regard to walking on a treadmill
and during the OWSs, this cohort of PAD participants who engaged in very few continuous 
bouts of moderate-to-vigorous physical activity experienced a very low number of events 
related to WPMs or SIWPs during their daily life. 
The walking capacity under daily life conditions in PAD participants remains largely 
understudied and, thus, poorly understood. In the present study, we focused on two different 
types of measurements that can provide complementary information to clinicians assessing 
the pain experienced by people with PAD under daily walking conditions. 
 
PFWT and MWT during an outdoor walking session 
The design of the OWS used in the present study was similar to that used in other studies 
assessing the outdoor walking capacity
6,7,15,16
 and is very similar to the design of walking
sessions performed during home-based walking programs
31
. To the best of our knowledge,
this study is the first to assess PFWT during outdoor walking in PAD participants. Using a 
GPS receiver, previous studies have reported a significant correlation between the MWT (or 
distance) during an outdoor walk and a treadmill-walking test in PAD participants
6,7
. Our
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results and the method proposed here extend the possibilities offered by wearable monitors in 
assessing outdoor walking capacity in PAD participants
11
.
First, by assessing the “natural” PFWT in addition to the MWT during outdoor walking, 
clinicians can fully assess the pain experienced by PAD participants for determining the 
baseline walking capacity and exploring the therapeutic effects of interventions. As 
previously reported regarding the maximal walking distance/time
7,15,16
, we found that the
PFWT during outdoor walking was significantly higher (by a factor of 3) than the PFWT 
measured during the Strandness treadmill test. This substantial variation supports the fact that 
participants rightly consider treadmill assessments a poor reflection of their walking 
disability
9
.
Second, the identification of SIWPs could improve the clinical interpretation of unsupervised 
outdoor walking capacity assessments. Indeed, by discriminating walking bouts that induce 
SIWPs during an OWS from those that do not, the risk of excluding participants who 
reported not stopping only because of leg-related symptoms could be considerably 
lowered
7,16
.
From a clinical utility perspective, the use of physical activity monitors has the potential of 
improving the clinical management of people with chronic conditions
32
. In the present case,
and although future studies should be performed, an outdoor assessment of PFWT (and 
MWT) using physical activity monitors could contribute to the better clinical management of 
PAD people for both diagnostic and therapeutic purposes as follows: 
 By complementing (not replacing) standardized treadmill evaluations to finely assess
the walking capacity of people with PAD under a context of "natural" walking and 
identify potential changes following interventions. 
 By providing a way to objectively assess the walking capacity of PAD people when
treadmill assessments are not available. 
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 By implementing efficient home-based walking programs with continuous monitoring
of walking capacity outcomes using wearable monitors during outdoor walking 
sessions. 
 
Daily life WPM in PAD 
While a prescribed OWS is a means of assessing the “natural” walking capacity under 
semicontrolled walking conditions, the aim of the 7-day FLM period was to explore the pain 
experienced by PAD participants in the daily life context. 
Methodological considerations. To develop our event-based analysis method to analyze the 
FLM period, one of the main methodological challenges for identifying WPMs and SIWPs 
from wearable monitor data was to discriminate walking bouts from non-walking bouts. 
Methodologies have been proposed in previous studies to discriminate walking from other 
behaviors, but these methodologies implement discrimination thresholds at the minute 
level
33
. In our study, because walking pain could occur at random in PAD participants, it was
crucial for our application to use a higher time resolution than that proposed in these studies. 
The use of a combination of two wearable monitors to label each event marker raised the 
issue of between-monitor synchronization. The preliminary tests performed prior to our study 
showed that the maximal time difference between the wGT3X+ monitor and the watch at the 
end of the 7-day period was 15 s (data not shown). Such a time difference was consistent 
with our labeling methodology and the use of a minimum duration of 15 s to define walking 
and non-walking bouts. 
Clinical interpretation. We found that on average, few events related to WPMs or SIWPs 
occurred on a daily basis in the PAD participants. Initially, this result could appear quite 
surprising considering both the treadmill and OWS results in our population and the high 
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level of disability reported by PAD participants in their daily life due to walking pain as 
demonstrated by the poor WIQ scores. 
Our population of PAD participants engaged in very few bouts of continuous moderate-to-
vigorous physical activity (see Table 4). Thus, although no causal inference can be drawn 
from our data, it could be suggested that such a pattern of daily physical activity prevents the 
occurrence of lower limb pain during walking in PAD participants. It is acknowledged that 
walking-induced pain is among the most frequent barriers to engaging in walking reported by 
PAD participants
18
. Thus, clinically, the low level of WPMs or SIWPs reported here during
the FLM periods basically show that the participants may be avoiding activity rather than that 
the participants were not functionally limited. Furthermore, although unlikely at the sample 
level and over the entire duration of the recording, it cannot be completely ruled out that 
weather conditions could have influenced the pattern of (outdoor) physical activity during the 
FLM period and, in turn, the occurrence of WPM. 
Independently or in conjunction with the pattern of daily physical activity, we found that the 
intensity of free-living walking as measured by the mean VM was lower than the walking 
intensity during the OWS. This finding could explain why the participants did not report a 
large number of WPM events. 
Taken together, our results support the well-known discrepancy between the leg-related 
symptoms reported (or not) by symptomatic (or asymptomatic) PAD participants and the 
actual impairment of their leg function when objectively assessed
34
. A conjunction of factors
likely explains the pattern of symptom occurrence during daily life in PAD participants. 
Clinicians should consider that a joint and objective assessment of physical activity and 
sedentary behaviors is important to fully assess the pain experienced by PAD participants 
under free-living conditions. 
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From a clinical utility perspective, qualitative studies have documented that living with PAD 
is associated with pain in daily life, which impairs and limits mobility
35
. Consequently,
physical and social functions are negatively affected, leading to a decreased quality of life
35
.
However, other than the knowledge provided by qualitative studies, no direct information is 
available regarding the pattern of walking pain in daily life, i.e., on a day-to-day basis. When 
and how often does ischemic pain occurs? Which type, duration and intensity of daily life 
activities are mainly “at risk” of causing ischemic pain? Does pain occurrence lead people 
with PAD to stop walking in all cases? Our opinion is that such information could help 
patients to better manage their “pain experience” and engage in daily walking. The method 
proposed here opens interesting opportunities to address these issues. 
 
Study limitations 
Some limitations of the present study should be acknowledged. First, although the missing 
data rate in the reporting of the WPMs or SIWPs during the OWS was low and the monitor-
wearing compliance during the 7-days of FLM was high, some participants highlighted that 
the watch should be more ergonomic to facilitate pressing the event marker button. This 
feedback may explain the high number of multiple presses performed by the participants to 
ensure the recording of the events. In the present study, we used a watch as an event recorder 
because the recording of event markers over a long period of time was feasible (>7 days at a 
5-s recording rate). To the best of our knowledge, no other technical solution was 
commercially available when we designed the present study. 
Second, we identified that the events related to WPMs or SIWPs during the seven days of 
FLM mainly occurred during continuous outside activities. Although this result seems to be 
consistent with the fact that a prolonged bout of walking could more likely occur when 
walking outside, it should be interpreted with caution because some timestamp distortions 
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could appear when the daily activities were recalled at bedtime and recorded by the 
participants in their diary. Adding a GPS receiver could have helped in performing this 
discrimination and could have increased the accuracy of our analysis of the FLM results. The 
use of a GPS receiver could add relevant information related to WPMs or SIWPs, such as the 
location (environmental context) and the indoor/outdoor context, the speed of the outdoor 
walk and the distance walked when it occurs. In the present study, the choice was made to not 
add a GPS receiver during the seven days of FLM to limit the burden on the participants due 
to wearing multiple physical activity monitors. Furthermore, the DG100 GPS receiver is not 
suitable for prolonged measurements, and the combination of the watch and a GPS receiver 
(instead of the accelerometer) could have precluded the analysis of any WPMs or SIWPs 
occurring indoors. 
Third, it is unknown whether, at the patient level, the experience of recording pain affects the 
experience of pain. This issue deserves further study. Finally, the VM count threshold used 
was derived from a previous study in which the authors applied this threshold to discriminate 
sedentary behaviors from physical activity
28
. To the best of our knowledge, no study has
proposed a specific count threshold to discriminate walking bouts from non-walking bouts at 
the second level. Although the counts threshold used in the present study appeared relevant 
when implementing our algorithm, future studies should refine this method. 
Future directions 
A first and important technical step could be to design a more suitable and ergonomic watch 
to facilitate the task for the participants when reporting events related to a WPM or SIWP. 
New technical solutions are currently under development (SHERPAM project: 
https://sherpam.cominlabs.u-
bretagneloire.fr/fr/aomi;jsessionid=FFDDF78A949065BC26AADFA3CC17C2AB). Future 
studies should also determine the interest in using or adding other types of wearable 
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monitors, such as a GPS receiver as explained above. Furthermore, the ActivPAL™ monitor 
could potentially facilitate the discrimination of marker events (WPMs and SIWPs), and the 
methodology proposed by Clarke et al. 
17
 should be considered in light of that proposed here.
We acknowledge that our methodology should be applied and tested in another population of 
PAD participants. We are confident about the external validity of this methodology because it 
did not appear to be patient-specific. The next step is to design cross-sectional studies 
involving a large sample of PAD participants to investigate the complex interactions among 
lower limb symptom occurrence during daily life, walking capacity, physical activity patterns 
and avoidance, and quality of life. 
 
PERSPECTIVE 
The present study proposes a new method using wearable monitors to objectively identify 
and quantify lower limb WPMs and SIWPs during OWSs and daily life in a sample of PAD 
participants. The PFWT and the MWT derived from this method were significantly correlated 
with treadmill measures of walking capacity. Assessing events related to WPMs or SIWPs in 
daily life can provide researchers and clinicians a more realistic and holistic view of the 
experience of living with PAD (burden of the disease) and the associated functional 
limitations and, consequently, could be a promising clinical and research tool for PAD 
management. 
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FIGURES LEGENDS 
Figure 1. Left panel: Schematic representation of the wearable monitor-based methodology 
developed to label each event marker recorded by the watch during the 7-day free-living 
measurement. Right panel: A typical example of the event identification performed in one 
patient. 
Legend 
VM: Vector magnitude. WPM: Walking pain manifestation. SIWP: Stop induced by walking 
pain. 
Left panel. The first step was to discriminate walking bouts from non-walking bouts using the 
VM count data recorded by the wGT3X+. This approach consisted of using a counts/s 
threshold as previously proposed to identify sedentary behavior in adults in free-living 
environments
28
. Our rationale was as follows: a string of consecutive count data with a VM
≥1 count/s for ≥15 s was defined as a walking bout and that with a VM=0 count/s for ≥15 s 
was defined as a non-walking bout. A string of consecutive count data with a VM ≥1 counts/s 
for <15 s was converted to a non-walking bout. Conversely, a string of consecutive counts 
data with a VM=0 count/s for <15 s was converted to a walking bout. The rationale of using a 
minimum duration of 15 s to define the walking and non-walking bouts was that walking-
induced ischemia was unlikely to appear (during walking) or disappear (during stopping) 
within such a short period
15
. An event marker was labeled a WPM when it occurred first
during a walking bout and at least ≥15 s after the beginning of the walking bout. A single or a 
double event marker was labeled as an SIWP when the marker occurred during the first 15 
seconds of a stopping bout that followed a walking bout or during the last 15 seconds of a 
walking bout immediately before a stopping bout. 
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Right panel. The upper right panel (A) shows the VM counts over time measured throughout 
an entire day (24 hours) in one patient. The events related to walking pain manifestation 
(WPM) and stop induced by walking pain (SIWP) recorded and processed using our 
methodology are also displayed on the graph. The color bars indicate when the patient was at 
home or outside on the basis of the information reported in the notebook. In the lower right 
panel (B), the time period during which a WPM or SIWP appeared (during this day in this 
patient) is presented. 
 
Figure 2. Pain free-walking times and maximal walking times in each context of 
measurement in PAD participants. 
Legend 
PFWT: Pain-free walking time. MWT: Maximal walking time. OWS: Outdoor walking 
session. FLM: 7-day free-living measurement. 
a: P<0.05 vs. Strandness test; b: P<0.05 vs. Gardner test; c: P<0.05 vs. outdoor walking 
session; d: P<0.05 vs. the 7-day free-living measurement period. 
 
Figure 3. Overview of the number of events related to lower limb pain manifestation and 
stop induced by walking pain per PAD patient. 
Legend 
WPM: Walking pain manifestation. SIWP: Stop induced by walking pain. 
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APPENDICES LEGENDS 
Appendix #1. Relationship between the walking capacity measured during the outdoor 
walking session and that measured during the treadmill tests. 
Legend 
PFWT: Pain-free walking time. MWT: Maximal walking time. OWS: Outdoor walking 
session. 
 
Appendix #2. Relationship between the walking capacity measured during the outdoor 
walking session and the scores obtained from the walking impairment questionnaire and the 
SF-36 questionnaire. 
Legend 
PFWT: Pain-free walking time. MWT: Maximal walking time. OWS: Outdoor walking 
session. WIQ: Walking impairment questionnaire. PFs: Physical functioning score. 
 
Appendix #3. Relationship between the average number of daily walking pain manifestation-
related events as assessed during the 7-day free-living measurement and some walking 
capacity measures. 
Legend 
PFWT: Pain-free walking time. MWT: Maximal walking time. WPM: Walking pain 
manifestation. OWS: Outdoor walking session. WIQ: Walking impairment questionnaire. 
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Table 1. Inclusion and non-inclusion criteria of the CLASH study. 
Inclusion criteria 
 Age ≥ 18 years old
 Insured under the French social security system (according to French law)
 Presence of lower-extremity peripheral artery disease, defined by:
o A resting ankle-brachial index (ABI) ≤ 0.90
o OR if resting ABI > 0.90 and < 1.00, a decrease in recovery ankle systolic
pressure or in recovery ABI from treadmill exercise higher than 30% or 20%, 
respectively (AHA recommendations). 
o OR if resting ABI > 1.40, a toe pressure index ≤ 0.70
 Maximal walking distance on treadmill (3.2 km/h, 10% grade) < 500ma
 Complain of exertional lower limbs pain that sometimes can begin at rest, causes the
participant to stop walking and relieves or lessens within 10 minutes of rest (assessed 
using the San Diego questionnaire AND confirmed during treadmill testing)
b
Non-inclusion criteria 
 Exercise limitation due to symptoms not related to an arterial insufficiency in the
lower limbs (e.g., dyspnea, angina pectoris) 
 Contraindication for walking (Abdominal aortic aneurysm > 4 cm)
 Myocardial infarction and no stroke in the last 3 months
 Critical limb ischemia, amputation.
 Pregnant women
 Adult subject to legal protection (guardianship or tutelage measure) and persons
deprived from their liberty (according to French law). 
 Patient living more than 50 km from the university hospital
 Patient unable to understand the instructions of the study
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a
As assessed during the medical appointment. 
b
 According to our inclusion criteria, PAD participants’ leg symptoms that fell within the 
following leg symptom categories 
13
 could be included in the study:
i) Intermittent claudication. Patients that experience exertional calf pain that does not
begin at rest and that forces them to stop walking and that relieves or lessens within 10 
minutes of rest; 
ii) Atypical exertional leg pain/stop. This category can encompass diverse situations of
exertional leg symptoms. In the present study, PAD participants in this category were 
included if they experience exertional pain that does not begin at rest and that forces 
them to stop walking, but that do not involve only the calf(s) but also thigh(s) and/or 
buttock(s). Further, the exertional leg pain relieves or lessens within 10 minutes of rest; 
iii) Leg pain on exertion and rest. In this category, people with PAD experience exertional
lower limbs pain during walking but sometimes this pain can begin at rest when they 
are standing still or sitting. As reminded by Criqui et al. (see reference #19), this 
category of people with PAD with “pain at rest” should not be confused with those that 
experience “rest pain”, which usually refers to people with such severe advanced PAD 
that ischemic pain is present even at rest. Subjects with ischemic rest pain were not 
included in the study. 
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Table 2. Characteristics of included peripheral arterial disease participants 
General 
Age, y 60±10 
Male sex, n (%) 20 (87) 
Stature, cm 169±8 
Body mass, kg 78.9±16.3 
Body mass index, kg/m
2
27.4±4.7 
Ankle-brachial index 0.61 [0.53;0.75] 
Leg symptoms reported / assessed on treadmill
†
, n (%)
Intermittent claudication Rose 17 (74) / 18 (78) 
     Leg pain on exertion and rest 5 (22) / 5 (22) 
     Atypical claudication-carry on 1 (4) / 0 (0) 
Comorbid conditions, n (%) 
Current smoker 11 (48) 
Former smoker 23 (100) 
Previous lower-extremity revascularization 8 (35) 
History of myocardial infarction 6 (26) 
Chronic bronchitis 6 (26) 
Diabetes mellitus 6 (26) 
Medications used, n (%) 
Antiplatelet agents 18 (78) 
Statins 21 (91) 
Anti-diabetics 5 (22) 
Vasodilators 4 (17) 
-blockers 6 (26) 
. 
A
cc
ep
te
d 
A
rt
ic
le
Antihypertensive drugs 14 (61) 
Treadmill walking capacity assessment 
Gardner-Skinner treadmill test 
Pain-free walking time, s 131 [89;224] 
Maximal walking time, s 289 [203;420] 
Strandness treadmill test 
Pain-free walking time, s 79 [56;105] 
Maximal walking time, s 178 [116;213] 
Questionnaires 
Short-form 36 
Physical functioning score (PFs) 50 [35;70] 
Role-physical score (RPs) 25 [0;100] 
Bodily pain score (BPs) 41 [31;42] 
General health score (GHs) 52 [30;62] 
Vitality score (VTs) 40 [25;60] 
Social functioning score (SFs) 63 [38;88] 
Role-emotional score (REs) 33 [0;100] 
Mental health (MHs) 68 [52;84] 
Physical component summary score (PCS) 34 [29;43] 
Mental component summary score (MCS) 42 [37;55] 
Walking impairment questionnaire 
Distance subscale score 20 [11;40] 
Speed subscale score 25 [17;33] 
Stairs climbing subscale score 42 [21;75] 
Total score 34 [17;49] 
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Continuous variables are expressed as medians with interquartile range [IQR = 25
th
;75th percentiles] or as
mean±SD. Data for categorical variables are expressed as a number (percentage). 
†
 Leg symptoms reported using the San Diego claudication questionnaire and then assessed during the 
treadmill tests; See Table 1 for definition. Atypical claudication-carry on category refers to PAD 
participants that experience exertional leg symptoms that do not begin at rest and that do not stop them 
from walking. 
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Table 3. Results from the outdoor walking session. 
Atmospheric conditions (mean±SD) 
Temperature, °C 15±5 
Relative humidity, % 68±15 
Atmospheric pressure, hPa 1020±10 
Wind speed, km/h 15±8 
GPS derived-parameters 
Median [IQR] duration of the session, min 52 [48;55] 
Mean±SD total distance, m 2474±957 
Mean±SD walking speed, km/h 4.2±0.4 
Median [IQR] number of stops 6 [4;10] 
Median [IQR] MWT, s 
 All walking bouts
 Longer walking bout
290 [164;358] 
329 [215;481] 
Median [IQR] duration of stops, min 1.72 [1.38;3.00] 
Accelerometer counts 
Mean ± SD VM, counts/s 64.9±20.4 
Observation-derived parameters 
WPM events, n 
126 
SIWP events, n 
170 
Median [IQR] PFWT, s 
 All walking bouts
 Longer walking bout
141 [62;217] 
187 [89;264] 
Median [IQR] MWT, s 
280 [157;347] 
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 All walking bouts
 Longer walking bout
327 [212;465] 
MML derived-parameters 
WPM events, n 115 
SIWP events, n 153 
Median [IQR] PFWT, s 
 All walking bouts
 Longer walking bout
163 [66;220] 
176 [95;270] 
Median [IQR] MWT, s 
 All walking bouts
 Longer walking bout
263 [164;353] 
326 [214;458] 
SD: Standard deviation. IQR: Interquartile range. GPS: Global positioning system. MML: Micro 
Motionlogger® Watch. VM: Vector magnitude. WPM: Walking pain manifestation. SIWP: Stop induced 
by walking pain. PFWT: Pain free walking time. MWT: Maximal walking time. 
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Table 4. Results from the seven days free-living measurement. 
WPM 
Total number 282 
Mean±SD event/week (range) 13±10 (0-30) 
Mean±SD event/day (range) 2±1 (0-5) 
Median [IQR] PFWT, sec 
All walking bouts 
Longer walking bout 
342 [272;434] 
778 [526;1163] 
Mean±SD VM, counts/s 46±15 
SIWP 
Total number 86 
Mean±SD event/week (range) 
4±6 (0-19) 
Mean±SD event/day (range) 1±1 (0-3) 
Median [IQR] PFWT, sec 
All walking bouts 
Longer walking bout 
433 [338;688] 
888 [505;1333] 
Mean±SD VM 43±19 
Physical activity level 
Median [IQR] Time spent, min/d 
Sedentary behaviors (SB) 
Light physical activity (LPA) 
Moderate physical activity (MPA) 
Vigorous physical activity (VPA) 
535 [442-608] 
234 [172-282] 
62 [47-121] 
0 [0-0] 
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Median [IQR] Percent of time, %/d 
Sedentary behaviors (SB) 
Light physical activity (LPA) 
Moderate physical activity (MPA) 
Vigorous physical activity (VPA) 
64 [52-72] 
27 [22-33] 
8 [5-15] 
0 [0-0] 
Median [IQR] number of bouts ≥ 10 min and ≥ 760 counts/min, n 2 [1-8] 
WPM: Walking pain manifestation; SIWP: Stop induced by walking pain. VM: Vector magnitude. 
SD: Standard deviation; IQR: Interquartile range 
SB level: counts/min< 100; LPA level: counts/min between 100 and 759; MPA level: counts/min between 
760 and 5724; VPA level: counts/min>5724 
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